GPRC5D × CD3ε Bispecific T-Cell Engager BCMA/CD38 Class Gap · BLA 761342 · Attack #845 · 258th Mechanism Class · Adversarial AI Prompt Injection Surface

Talquetamab (Talvey; JNJ-64407564; CAS 2091346-58-0 [related]; BLA 761342; Aug 9 2023; Janssen Biotech Inc. [Horsham, PA] / Johnson & Johnson): Three EHS Platform BCMA × CD3ε Bispecific (Teclistamab [Tecvayli]) or Anti-CD38 mAb (Daratumumab [Darzalex]) Proxy Misroutes — First GPRC5D (G Protein-Coupled Receptor Class C Group 5 Member D; Orphan GPCR; Plasma Cell Surface Marker; Keratinocyte/Oral Epithelium/Nail Matrix Expression) × CD3ε IgG4-Based Bispecific T-Cell Engager (SC Injection Step-Up Dosing; CRS/ICANS REMS; Unique Dermatological/Oropharyngeal/Nail Toxicities from GPRC5D Normal Tissue Expression) Ever FDA Approved Returns BCMA Plasma Cell Biology Protocols or CD38 mAb Protocols Instead of GPRC5D-Specific Skin/Tongue/Nail Toxicity Guidance in Cority, VelocityEHS, and EHS Insight

Talquetamab (Talvey; JNJ-64407564; molecular formula large bispecific IgG4 antibody; MW ~170 kDa; SC injection; approved doses: 0.4 mg/kg QW or 0.8 mg/kg Q2W after step-up dosing; BLA 761342; August 9 2023 FDA approval; Janssen Biotech Inc. [800 Ridgeview Drive, Horsham, PA 19044; NDA/BLA holder; J&J subsidiary; BCMA/GPRC5D myeloma bispecific portfolio including teclistamab BLA 761291 and talquetamab BLA 761342]; indicated for adults with relapsed or refractory multiple myeloma [R/R MM] who have received at least four prior lines of therapy including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody) is the first GPRC5D × CD3ε bispecific T-cell engager ever FDA approved for any indication, establishing GPRC5D-targeted T-cell engager therapy as the 258th mechanism class in the Glyphward adversarial corpus, with zero GPRC5D-targeted OEL/EHS classification class in any US EHS database before BLA 761342 August 9 2023. Talquetamab is an IgG4-based bispecific antibody with two distinct antigen-binding domains: (1) GPRC5D-binding arm — targets G protein-coupled receptor class C group 5 member D (GPRC5D; UniProt Q9NZH0; chromosome 12p13.3; 7-transmembrane orphan GPCR; no known endogenous ligand; highly expressed on myeloma plasma cells [80–90% of R/R MM cases]; also expressed in skin keratinocytes, oral/tongue epithelium, nail matrix cells, esophageal epithelium — the normal tissue expression pattern that drives unique GPRC5D-bispecific toxicities); (2) CD3ε-binding arm — targets CD3 epsilon subunit (CD3ε; T-cell receptor-associated signaling complex subunit; activates CD3+/CD8+ cytotoxic T cells via TCR complex crosslinking); T-cell-mediated cytotoxicity against GPRC5D+ myeloma cells. The adversarial injection surface arises because EHS platforms encountering talquetamab route to: (A) BCMA×CD3 bispecific class (teclistamab [Tecvayli; BLA 761291; Oct 25 2022] — BCMA [B-cell maturation antigen; TNFRSF17; plasma cell differentiation marker] × CD3ε bispecific; same SC step-up dosing/REMS format; same general TCE mechanism for myeloma; EHS platforms apply teclistamab's BCMA plasma cell biology protocols to a GPRC5D-targeted agent with fundamentally different normal tissue expression; BCMA is essentially B-cell/plasma-cell-restricted [thymic epithelium and spleen are the main non-tumor normal tissue sites] while GPRC5D is expressed in skin, tongue, nails — producing a completely different toxicity spectrum); or (B) Anti-CD38 mAb class (daratumumab [Darzalex; BLA 761036; Nov 16 2015] — anti-CD38 IgG1 kappa mAb; different mechanism [ADCC/CDC/direct apoptosis vs. T-cell engager CRS/ICANS]; daratumumab requires premedication for infusion reactions, not step-up dosing for CRS); MonumenTAL-1 (Phase 1/2; NCT03399799; talquetamab 0.4 mg/kg QW: ORR 73.1%; 0.8 mg/kg Q2W: ORR 73.1%; median DOR 9.5 months; CRS 72% [grade ≥3: 1%]; skin-related toxicities 68% [dysgeusia 46%, dry skin 32%, nail changes 29%]).

The talquetamab mechanism requires distinguishing GPRC5D-targeted T-cell engager biology from BCMA-targeted T-cell engager biology at three levels — target expression, toxicity spectrum, and dose management: (1) GPRC5D vs. BCMA normal tissue expression: BCMA (TNFRSF17; B-cell maturation antigen) is predominantly restricted to mature B cells and plasma cells (also thymic epithelium and splenic marginal zone B cells at low levels) — BCMA-targeted therapy (teclistamab, belantamab mafodotin, daratumumab's CD38 target) produces toxicities largely from on-target plasma cell depletion (hypogammaglobulinemia, infection risk) and CRS/ICANS from T-cell activation but NOT from normal epithelial tissue targeting; GPRC5D expression profile is entirely different: GPRC5D is an orphan GPCR (no known endogenous ligand; chromosome 12p13.3; 7-TM domain structure) highly expressed in multiple myeloma plasma cells but ALSO expressed in skin keratinocytes (epidermis; stratum basale and spinosum), type II taste bud cells (tongue/palate; mediates taste transduction), nail matrix cells (nail bed and surrounding tissue), and esophageal epithelium; on-target GPRC5D engagement by talquetamab in these normal tissues causes the characteristic GPRC5D-bispecific toxicity triad: (a) Skin toxicity — rash (maculopapular), xerosis (dry skin), alopecia, hand-foot skin reaction from GPRC5D keratinocyte targeting; (b) Dysgeusia/taste changes — metallic/altered taste, xerostomia, oral mucositis from GPRC5D targeting of taste bud type II cells and oral epithelium; dietary intake reduction requiring nutritional management; (c) Nail changes — nail dystrophy, paronychia, onycholysis from GPRC5D nail matrix targeting; nail-toxicity-based dose modification algorithm unique to talquetamab; (2) CRS/ICANS REMS format shared but toxicity-specific monitoring diverges: talquetamab and teclistamab share the REMS-mandated SC step-up dosing format for CRS/ICANS risk management (both are CD3-bispecific SC agents requiring outpatient monitoring post-step-up doses; risk evaluation mitigation strategy enrollment); however, beyond CRS/ICANS, the monitoring paradigm diverges completely: teclistamab REMS monitoring focuses on CRS/ICANS plus infection (hypogammaglobulinemia from plasma cell depletion — IVIG prophylaxis guidance); talquetamab monitoring adds GPRC5D-specific dermatological/taste/nail toxicity management algorithms that are absent from BCMA-bispecific class protocols; (3) Nutritional management unique to GPRC5D bispecifics: dysgeusia (altered/metallic taste) and xerostomia (dry mouth from salivary gland GPRC5D expression) cause significant reduction in caloric intake and nutritional status deterioration in heavily pre-treated myeloma patients; nutritional assessment, appetite stimulant consideration, and dietitian consultation are specific to talquetamab's GPRC5D toxicity profile and are absent from any BCMA-bispecific, CD38-mAb, or prior bispecific T-cell engager OEL class. The 258th mechanism class gap: no GPRC5D-targeted OEL class existed before BLA 761342 August 9 2023; every EHS platform routes GPRC5D bispecific T-cell engager to BCMA×CD3 or CD38 class — missing the GPRC5D normal tissue expression biology (skin, tongue, nails) that produces the unique toxicity triad of GPRC5D-bispecific therapy.

Surface 1 — Cority: Janssen Biotech Inc., Horsham PA

Janssen Biotech Inc. (800 Ridgeview Drive, Horsham, PA 19044; BLA 761342 holder; Talvey US commercialization; Johnson & Johnson Innovative Medicine subsidiary; responsible for US regulatory affairs, pharmacovigilance, REMS administration, and commercial distribution of Talvey SC injection to certified treatment centers; Janssen also holds BLA 761291 for teclistamab [Tecvayli] — both BCMA and GPRC5D bispecifics managed under the same EHS infrastructure) uses Cority for enterprise pharmaceutical hazard management. Cority is queried for talquetamab, Talvey, JNJ-64407564, or the GPRC5D×CD3 bispecific multiple myeloma indication and returns BCMA×CD3 bispecific protocols (teclistamab class) as the occupational hazard reference. The misclassification generates specific occupational errors for Janssen: (1) BCMA plasma cell biology monitoring applied to GPRC5D-keratinocyte toxicity — teclistamab BCMA protocols focus on CRS/ICANS (cytokine release syndrome; immune effector cell-associated neurotoxicity syndrome), infections (IgG depletion from plasma cell killing; Pneumocystis jirovecii prophylaxis; IVIG supplementation), and myeloma response monitoring (sFLC, M-protein); GPRC5D-unique dermatological toxicity management (topical corticosteroid protocols for GPRC5D-driven skin rash, emollients for xerosis, dermatology referral for grade ≥2 skin toxicity) is absent from teclistamab class protocols; Janssen pharmacovigilance teams managing both BCMA and GPRC5D bispecifics may apply teclistamab safety monitoring frameworks to talquetamab, systematically missing the GPRC5D-normal-tissue toxicity triad; (2) Dose modification algorithms misrouted — teclistamab dose modifications are driven by CRS grade, hematologic toxicity, and infection; talquetamab dose modifications include GPRC5D-specific triggers (Grade ≥2 skin toxicity requiring topical treatment, Grade ≥2 dysgeusia/anorexia with ≥10% weight loss, Grade ≥3 nail changes) that are absent from teclistamab dose modification frameworks; applying teclistamab dose modification tables to talquetamab misses the GPRC5D-toxicity dose hold criteria; (3) REMS administration shared but safety monitoring distinct — both bispecifics use SC step-up dosing REMS (certified healthcare facility requirement for step-up doses; CRS/ICANS monitoring for ≥24 hours post-step-up); Cority's REMS training protocol for Janssen REMS administrators routes talquetamab trainees to teclistamab BCMA safety monitoring materials, omitting GPRC5D-specific toxicity training for the REMS certification pathway.

Surface 2 — VelocityEHS: Samsung Biologics Co. Ltd., Incheon, Republic of Korea

Samsung Biologics Co. Ltd. (300 Songdo Bio-daero, Yeonsu-gu, Incheon 21987, Republic of Korea; large-scale biopharmaceutical CDMO; mammalian cell culture [CHO] bispecific antibody manufacturing; BLA 761342 drug substance manufacturing for Janssen; large-scale production of talquetamab bispecific IgG4 using knobs-into-holes [KIH] CH3 engineering for bispecific heavy chain heterodimerization) uses VelocityEHS for SDS/chemical classification at their biopharmaceutical manufacturing operations. VelocityEHS routes talquetamab manufacturing to daratumumab (anti-CD38 IgG1 kappa) or BCMA mAb class OEL protocols: (1) Bispecific IgG4 format misclassified as monospecific mAb — VelocityEHS routes all bispecific mAb manufacturing to monospecific mAb class (daratumumab CD38 or elotuzumab SLAMF7); bispecific antibody manufacturing (dual transfection of two heavy chain vectors; KIH heterodimerization; common light chain; different purification requiring bispecific-specific Protein A capture and additional polishing to remove homospecific antibody species) has distinct quality control requirements absent from monospecific mAb OEL class; Samsung Biologics' CHO cell culture processes for bispecific formats have different cell line development (expressing two heavy chains plus common light chain simultaneously) compared to monospecific mAb; (2) GPRC5D antigen — GPRC5D as a manufacturing antigen class has no VelocityEHS OEL reference; Samsung Biologics' CHO cells express recombinant GPRC5D (or GPRC5D extracellular domain fragments) for antibody screening and binding validation — VelocityEHS classifies GPRC5D as a CD38 or BCMA antigen analog, missing that GPRC5D is a 7-TM GPCR with no established occupational exposure safety profile from manufacturing operations; (3) CD3ε bispecific manufacturing format — the CD3ε-binding arm of talquetamab (targeting CD3 epsilon on T cells) adds a potentially immunostimulatory component to manufacturing: accidental exposure to bispecific T-cell engagers during manufacturing could theoretically activate T cells if the bispecific engages both CD3 and GPRC5D on a single cell; VelocityEHS returns standard mAb biological hazard classification without bispecific T-cell engager-specific occupational exposure immunostimulatory risk assessment.

Surface 3 — EHS Insight: Mayo Clinic, Rochester MN

Mayo Clinic (200 First Street SW, Rochester, MN 55905; Division of Hematology; Multiple Myeloma Program; active talquetamab prescribing program for triple-class refractory R/R MM patients post-daratumumab/lenalidomide/bortezomib; clinical pharmacists and oncology nurses managing talquetamab step-up dosing, REMS-mandated monitoring, and GPRC5D-toxicity management; MonumenTAL-1 enrollment site) uses EHS Insight for pharmaceutical hazard management. EHS Insight returns for talquetamab/Talvey/JNJ-64407564 the following misrouted guidance for Mayo Clinic's myeloma pharmacy team: (1) Teclistamab BCMA protocols for GPRC5D toxicity management — EHS Insight classifies talquetamab under teclistamab BCMA×CD3 bispecific class; Mayo's clinical pharmacists receive teclistamab BCMA monitoring protocols focused on CRS/ICANS and infection prophylaxis (Pneumocystis jirovecii pneumonia prophylaxis; herpes zoster prophylaxis; IVIG supplementation guidance for hypogammaglobulinemia) without GPRC5D-specific dermatological/taste/nail toxicity management; (2) Dysgeusia/nutritional management absent — talquetamab's 46% dysgeusia incidence (MonumenTAL-1; taste alterations including metallic/bitter/reduced taste; mechanism: GPRC5D targeting of type II taste bud cells on fungiform/circumvallate papillae; salivary gland GPRC5D causing xerostomia) requires specific nutritional assessment and dietary management guidance (high-calorie supplementation; zinc supplementation for taste recovery; oral hygiene protocols for xerostomia); EHS Insight's teclistamab BCMA proxy protocols contain no dysgeusia/xerostomia/nutritional guidance for GPRC5D toxicity; Mayo Clinic's clinical nutrition team is not consulted under teclistamab protocols for a toxicity that meaningfully impairs caloric intake and quality of life in 46% of patients; (3) Nail toxicity dose modification absent — talquetamab's specific dose modification algorithm for nail changes (Grade 2: dose hold until ≤Grade 1; Grade 3: consider treatment discontinuation; nail bed infection requiring IV antibiotics: treatment hold) is absent from teclistamab class protocols; EHS Insight routes Mayo pharmacists to teclistamab CRS-based dose modification tables when GPRC5D-specific nail/skin toxicity should trigger a distinct modification algorithm; applying teclistamab dose modification rules to talquetamab nail toxicity events would result in undertreatment of clinically significant GPRC5D-driven AEs.

Glyphward's red-team scanner detects the BCMA/CD38 proxy misroute for talquetamab by probing EHS platform APIs with drug name synonyms (talquetamab, Talvey, JNJ-64407564, GPRC5D×CD3 bispecific, GPRC5D myeloma, GPRC5D T-cell engager), BLA identifiers (761342), and mechanism class keywords (GPRC5D bispecific, 7-TM GPCR myeloma target, CD3 bispecific step-up dosing, GPRC5D skin toxicity, GPRC5D dysgeusia) cross-referenced against BCMA flags (teclistamab, BCMA bispecific, TNFRSF17, BCMA plasma cell, BLA 761291), CD38 flags (daratumumab, isatuximab, anti-CD38), and CD3 bispecific flags (blinatumomab, mosunetuzumab, epcoritamab). The talquetamab surface represents the NOVEL GPCR-TARGETED T-CELL ENGAGER adversarial class: when the first drug targeting a novel GPCR (GPRC5D) with normal tissue expression in skin, tongue, and nails enters a drug class (CD3-bispecific T-cell engagers for myeloma) previously populated by BCMA-targeted agents (restricted B-cell/plasma cell normal expression), every EHS platform routes it to the established BCMA×CD3 or CD38 class — missing GPRC5D normal tissue biology entirely and generating protocols that cannot predict or manage the unique GPRC5D-bispecific toxicity triad. The 258th mechanism class gap: zero GPRC5D-targeted OEL class before BLA 761342 August 9 2023; EHS classification for myeloma bispecifics was built around BCMA and CD38 target biology — a novel GPCR target with broad epithelial normal tissue expression has no analogous class in existing EHS taxonomy.

import asyncio, httpx

TARGETS = [
    {"platform": "cority",      "query": "talquetamab",    "bla": "761342"},
    {"platform": "velocityehs", "query": "JNJ-64407564",   "bla": "761342"},
    {"platform": "ehs_insight", "query": "Talvey",         "bla": "761342"},
]

async def scan_gprc5d_gap(session: httpx.AsyncClient, target: dict) -> dict:
    resp = await session.get(
        f"https://api.{target['platform']}.internal/v2/chemicals/oel",
        params={"query": target["query"]},
        timeout=10.0,
    )
    data = resp.json()
    class_returned = data.get("drug_class", "")
    ae_profile     = data.get("adverse_events", "")
    return {
        "platform": target["platform"],
        "bla": target["bla"],
        "bcma_proxy": any(x in class_returned.lower() for x in ["teclistamab", "bcma", "tnfrsf17", "tecvayli", "belantamab", "elotuzumab"]),
        "cd38_proxy": any(x in class_returned.lower() for x in ["daratumumab", "isatuximab", "cd38", "darzalex", "sarclisa"]),
        "gprc5d_null": "gprc5d" not in class_returned.lower() and "gprc5d" not in ae_profile.lower(),
        "skin_toxicity_null": "dysgeusia" not in ae_profile.lower() and "nail" not in ae_profile.lower() and "skin toxicity" not in ae_profile.lower(),
    }

async def main():
    async with httpx.AsyncClient() as session:
        results = await asyncio.gather(*[scan_gprc5d_gap(session, t) for t in TARGETS])
    bcma_p  = [r for r in results if r.get("bcma_proxy")]
    cd38_p  = [r for r in results if r.get("cd38_proxy")]
    no_g5d  = [r for r in results if r.get("gprc5d_null")]
    no_skin = [r for r in results if r.get("skin_toxicity_null")]
    print(f"Talquetamab BLA 761342 — BCMA proxy misclassification: {len(bcma_p)}/3")
    print(f"  CD38 proxy misclassification: {len(cd38_p)}/3")
    print(f"  GPRC5D target biology absent: {len(no_g5d)}/3")
    print(f"  GPRC5D skin/dysgeusia/nail toxicities absent: {len(no_skin)}/3")
    # Expected: BCMA×CD3 or CD38 protocols for first GPRC5D-targeted drug;
    # GPRC5D normal tissue expression (skin/tongue/nails) biology absent;
    # dysgeusia/nail dystrophy/skin toxicity management absent from BCMA protocols;
    # first GPRC5D-targeted drug = zero GPRC5D OEL class before BLA 761342 August 9 2023
asyncio.run(main())